Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 248-261

  Gkotzamanidou, Maria ^a   Papadimitriou, Christos A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

ASCT; Autologous stem cell transplantation; High dose chemotherapy; Peripheral T cell lymphoma; PTCL; Transplantation

Indexed keywords

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; HUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE;

AAIPI; ACVBP; AGE-ADJUSTED IPI; AITL; ALCL; ALK; ALLO-SCT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPLASTIC LARGE CELL LYMPHOMA; ANAPLASTIC LYMPHOMA KINASE; ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA; ANTI-THYMOCYTE GLOBULIN; ASCT; ATG; AUTOLOGOUS STEM CELL TRANSPLANTATION; B; BCNU; BCNU, ETOPOSIDE, CYCLOPHOSPHAMIDE; BCNU, ETOPOSIDE, CYTARABIN, CYCLOPHOSPHAMIDE; BCNU, ETOPOSIDE, CYTARABIN, MELPHALAN; BEAC; BEAM; BEC; BUSULFAN; BUSULFAN, ETOPOSIDE, CYCLOPHOSPHAMIDE; C; CARMUSTINE; CEOP; CHOEP; CISPLATIN; COMPLETE RESPONSE (CR1/2 FIRST/SECOND COMPLETE REMISSION); CR; CTCL; CUTANEOUS T-CELL LYMPHOMA; CVB; CVB/CBV; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE, EPIRUBICIN, VINCRISTINE, PREDNISONE; CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN, ETOPOSIDE, PREDNISONE; CYT; CYTARABIN; DEXAMETHASONE, CYTARABINE, CISPLATIN; DFS; DHAP; DIFFUSE LARGE B-CELL LYMPHOMA; DISEASE-FREE SURVIVAL; DLBL; DOXORUBICIN, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, PREDNISONE, INTRATHECAL METHOTREXATE; E; EATL; ECVBP; EFS; ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA; EPIRUBICIN, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, PREDNISONE; ETOPOSIDE; EVENT-FREE SURVIVAL; FLU; FLUDARABINE; GRAFT-VERSUS-HOST DISEASE; GVHD; HEPATOSPLENIC T-CELL LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; HSTL; ICE; IFE; IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE; IFOSFAMIDE, ETOPOSIDE; INTENTION TO TREAT POPULATION; INTERNATIONAL PROGNOSTIC INDEX; IPI; ITTP; MA/MAC; MCEC; MEL; MELPHALAN; MITO; MITOXANTRONE; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NATURAL KILLER-CELL/T-CELL LEUKEMIA/LYMPHOMA; NK; NK/T; NON-RELAPSE MORTALITY; NRM; ORR; OS; OVERALL RESPONSE RATE; OVERALL SURVIVAL; P; PARTIAL REMISSION; PERIPHERAL T-CELL LYMPHOMA; PFS; PIF; PR; PREDNISONE, METHOTREXATE, DOXORUBICIN, CYCLOPHOSPHAMIDE, ETOPOSIDE-CYTARABINE, BLEOMYCIN, VINCRISTINE, METHOTREXATE; PRIMARY INDUCTION FAILURE; PROGRESSION-FREE SURVIVAL; PROMACE-CYTBOM; PTCL; RANIMUSTINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN; REDUCED INTENSITY CONDITIONING; RIC; TBI; THIO; THIOTEPA; TIME TO TREATMENT FAILURE; TOTAL BODY IRRADIATION; TRANSPLANTATION; TREATMENT-RELATED MORTALITY; TRM; TTF; W; WEEKS; Y; YEAR;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84892556579     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.016     Document Type: Review

References (86)

1. No authors listed A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89(11):3909-3918.
2. Rudiger T., Weisenburger D.D., Anderson J.R., et al. Peripheral T-cell lymphoma (excluding anaplastic largecell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 2002, 13(1):140-149.
3. Abouyabis A.N., Shenoy P.J., Lechowicz M.J., Flowers C.R. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008, 49(11):2099-2107.
4. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
5. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood 2011, 117(12):3402-3408.
6. Ansell S.M., Habermann T.M., Kurtin P.J., et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997, 15(6):2296-2301.
7. Sonnen R., Schmidt W.P., Muller-Hermelink H.K., Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005, 129(3):366-372.
8. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103(7):2474-2479.
9. Went P., Agostinelli C., Gallamini A., et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006, 24(16):2472-2479.
10. Dupuis J., Emile J.F., Mounier N., et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006, 108(13):4163-4169.
11. Rodriguez J., Conde E., Gutierrez A., et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007, 92(8):1067-1074.
12. Pescarmona E., Pignoloni P., Puopolo M., et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol 2001, 195(3):361-366.
13. Rassidakis G.Z., Jones D., Lai R., et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol 2003, 200(2):240-248.
14. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20(10):2472-2479.
15. Mounier N., Gisselbrecht C., Briere J., et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004, 15(12):1790-1797.
16. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20(9):1533-1538.
17. Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79(1):32-38.
18. Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19(5):958-963.
19. Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27(1):106-113.
20. Nickelsen M., Ziepert M., Zeynalova S., et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009, 20(12):1977-1984.
21. D'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30(25):3093-3099.
22. Rodriguez J., Conde E., Gutierrez A., et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007, 78(4):290-296.
23. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18(4):652-657.
24. Feyler S., Prince H.M., Pearce R., et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007, 40(5):443-450.
25. Kyriakou C., Canals C., Goldstone A., et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26(2):218-224.
26. Prochazka V., Faber E., Raida L., et al. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011, 155(1):63-69.
27. Numata A., Miyamoto T., Ohno Y., et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010, 45(2):311-316.
28. Beitinjaneh A., Saliba R., Okoroji G., et al. Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for non cutaneous T-cell lymphoma (TCL): the university of Texas M.D. Anderson cancer center (MDACC) experience. ASCO Meeting Abstr 2011, 29(Suppl. 15):6565.
29. Hwang W.Y., Koh L.P., Lim S.T., et al. Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphoma. Leuk Lymphoma 2011, 52(7):1382-1386.
30. Ahn J.S., Yang D.H., Jung S.H., et al. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol 2013, January 29 [Epub ahead of print] PMID: 23358616.
31. Smith S.M., Burns L.J., van Besien K., et al. Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. J Clin Oncol 2013, July 29 [Epub ahead of print] PMID: 23897963.
32. Mounier N., Gisselbrecht C., Briere J., et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2004, 22(14):2826-2834.
33. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333(23):1540-1545.
34. Vose J.M., Peterson C., Bierman P.J., et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 1990, 76(2):424-431.
35. Fanin R., Ruiz de Elvira M.C., Sperotto A., Baccarani M., Goldstone A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999, 23(5):437-442.
36. Rodriguez J., Munsell M., Yazji S., et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19(17):3766-3770.
37. Blystad A.K., Enblad G., Kvaloy S., et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001, 27(7):711-716.
38. Song K.W., Mollee P., Keating A., Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120(6):978-985.
39. Rodriguez J., Caballero M.D., Gutierrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003, 14(12):1768-1775.
40. Schetelig J., Fetscher S., Reichle A., et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003, 88(11):1272-1278.
41. Zamkoff K.W., Matulis M.D., Mehta A.C., Beaty M.W., Hutchison R.E., Gentile T.C. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004, 33(6):635-638.
42. Jantunen E., Wiklund T., Juvonen E., et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004, 33(4):405-410.
43. Jagasia M., Morgan D., Goodman S., et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004, 45(11):2261-2267.
44. Kewalramani T., Zelenetz A.D., Teruya-Feldstein J., et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006, 134(2):202-207.
45. Kim M.K., Kim S., Lee S.S., et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 2007, 86(6):435-442.
46. Smith S.D., Bolwell B.J., Rybicki L.A., et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007, 40(3):239-243.
47. Chen A.I., McMillan A., Negrin R.S., Horning S.J., Laport G.G. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008, 14(7):741-747.
48. Lee J., Au W.Y., Park M.J., et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008, 14(12):1356-1364.
49. Yang D.H., Kim W.S., Kim S.J., et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009, 15(1):118-125.
50. Mak V., Connors J.M., Klasa R., et al. Survival of peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors. Blood 2011, 118. [Abstract 96; ASH Annual Meeting Abstracts].
51. Nademanee A., Palmer J.M., Popplewell L., et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transplant 2011, 17(10):1481-1489.
52. Czyz A., Romejko-Jarosinska J., Helbig G., et al. Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis. Ann Hematol 2013, Mar 8 [Epub ahead of print] PMID: 23471671.
53. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22(11):2172-2176.
54. Murashige N., Kami M., Kishi Y., et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005, 130(4):561-567.
55. Hamadani M., Awan F.T., Elder P., et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008, 14(4):480-483.
56. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008, 26(14):2264-2271.
57. Kyriakou C., Canals C., Finke J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009, 27(24):3951-3958.
58. Dodero A., Spina F., Narni F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012, 26(3):520-526.
59. Kanakry J.A., Kasamon Y.L., Gocke C.D., et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013, 19(4):602-606.
60. O'Connor O.A., Hamlin P.A., Portlock C., et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007, 139(3):425-428.
61. O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29(9):1182-1189.
62. Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31(1):104-110.
63. Lee J., Suh C., Kang H.J., et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008, 19(12):2079-2083.
64. Kim S.J., Yoon D.H., Kang H.J., et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012, 48(17):3223-3231.
65. Dueck G., Chua N., Prasad A., et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116(19):4541-4548.
66. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25(21):3109-3115.
67. Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117(22):5827-5834.
68. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30(6):631-636.
69. Gloucester Pharmaceuticals Inc. Romidepsin: Sponsor's background package for the Oncologic Drugs Advisory Committee Meeting, September 2 2009, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180633.pdf.
70. Marchi E., Alinari L., Tani M., et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005, 104(11):2437-2441.
71. Dong M., He X.H., Liu P., et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 2013, 30(1):351.
72. Zinzani P.L., Venturini F., Stefoni V., et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010, 21(4):860-863.
73. Rupoli S., Goteri G., Picardi P., et al. Alemtuzumab in combination with interferon-α or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: report of preliminary results. Blood 2008, 112. [Abstract 2005; ASH Annual Meeting Abstracts].
74. ®) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL). Blood 2008, 112. [Abstract 2005; ASH Annual Meeting Abstracts].
75. Dhillon N., Bakkannagari S., Chaan N.G., Lim J., Duvic M., Kurzrock R. Cutaneous T cell lymphoma: responses in phase 1 trial of combination therapy with liposomal doxorubicin, bortezomib, and gemcitabine. Blood 2006, 108. [Abstract 2466; ASH Annual Meeting Abstracts].
76. Mahadevan D., Unger J.M., Spier C.M., et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013, 119(2):371-379.
77. Bartlett N.L., Younes A., Carabasi M.H., et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111(4):1848-1854.
78. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363(19):1812-1821.
79. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25(19):2764-2769.
80. Shustov A.R., Advani R., Brice P., et al. Complete remissions with Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. ASH Ann Meeting Abstr 2010, 116(21):961.
81. Chen R., Gopal A.K., Smith S.E., et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010, 116. [Abstract 283; ASH Annual Meeting Abstracts].
82. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30(18):2183-2189.
83. Kim J.G., Sohn S.K., Chae Y.S., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60(1):129-134.
84. Kim S.J., Kim K., Kim B.S., et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 2009, 20(2):390-392.
85. Kim S.J., Kim K., Park Y., et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 2012, 30(1):368-375.
86. Clinical trials.gov. [website] [Accessed 03.03.13].